Wolf-Hirschhorn Syndrome — a rare chromosomal microdeletion syndrome caused by heterozygous deletion of the distal portion of the short arm of chromosome 4 (4p16.3), encompassing critical genes including WHSC1 (Wolf-Hirschhorn syndrome candidate 1, also known as NSD2/MMSET) and LETM1, with an estimated prevalence of 1 in 50,000 live births and a female-to-male ratio of approximately 2:1 reflecting the higher proportion of females among liveborn WHS cases — was simultaneously described in 1965 by Herbert Wolf and colleagues and independently by Kurt Hirschhorn and colleagues, producing the classic "Greek warrior helmet" facial appearance whose characteristic features — widely spaced eyes, broad beaked nose, prominent glabella, high arched eyebrows, and short philtrum — represent the clinical hallmark that facilitates recognition across the phenotypic spectrum. The 4p16.3 deletion underlying Wolf-Hirschhorn Syndrome arises de novo in approximately 85–90% of cases through interchromosomal recombination or chromatin rearrangement during meiosis, with approximately 10–15% resulting from segregation of a parental chromosomal rearrangement such as a translocation or inversion — a proportion clinically significant because inherited deletions carry a substantial recurrence risk that requires parental karyotyping and prenatal diagnosis coordination for subsequent pregnancies. The clinical phenotype of Wolf-Hirschhorn Syndrome is characterized by a deletion-size-dependent spectrum in which the critical region at 4p16.3 produces the core features while larger deletions extending proximally produce more severe intellectual disability and additional congenital anomalies; core features include severe to profound intellectual disability in larger deletions and moderate intellectual disability in smaller deletions; seizures occurring in approximately 90% of affected individuals, representing the most clinically significant and potentially life-threatening complication of the syndrome, encompassing a range of seizure types including infantile spasms, myoclonic seizures, atonic seizures, absence seizures, and generalized tonic-clonic seizures that are frequently medically refractory and evolve across the lifespan; growth retardation that begins in utero and produces significant short stature and underweight; feeding difficulties in infancy from hypotonia, poor suck reflex, and oropharyngeal dysphagia requiring nasogastric tube or gastrostomy tube feeding in a significant proportion; congenital heart defects in approximately 30–50%; skeletal anomalies including scoliosis, hip dysplasia, and joint hypermobility; immune deficiency with recurrent otitis media and sinopulmonary infections; renal anomalies; hypospadias in males; and hearing loss. The near-universal seizure disorder in Wolf-Hirschhorn Syndrome — with onset typically in the first year of life, high medical refractoriness, and a tendency toward seizure clustering and status epilepticus in a significant subset — makes epilepsy monitoring platform availability and seizure tracking alert system reliability among the highest clinical priorities in WHS technology platform design.
Wolf-Hirschhorn Syndrome technology platforms — whether supporting WHS patient registry systems collecting genotype-phenotype data, seizure frequency and type records, anti-epileptic drug treatment outcome records, and natural history outcomes for the rare disease research community; epilepsy monitoring platforms managing seizure diary records, EEG interpretation records, anti-epileptic drug pharmacokinetic monitoring, seizure alert system data, and status epilepticus emergency protocol records; feeding and nutritional management tools tracking nasogastric and gastrostomy feeding tolerance, growth velocity, nutritional adequacy, and feeding therapy progress; heartbeat monitoring systems for seizure tracking alert platforms whose sub-minute detection capability protects against undetected nocturnal seizure clusters and status epilepticus; and developmental therapy scheduling platforms coordinating physical therapy, occupational therapy, speech-language pathology, vision therapy, and behavioral support across the lifespan — must maintain the availability and performance standards demanded by the epileptic, nutritional, developmental, cardiovascular, and multisystem complexity of modern Wolf-Hirschhorn Syndrome care. This guide explains why Wolf-Hirschhorn Syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the chromosomal microdeletion, epileptic, nutritional, developmental, and cardiovascular complexity of WHS management.
Why Wolf-Hirschhorn Syndrome Tech Platforms Require Specialized Monitoring Attention
Wolf-Hirschhorn Syndrome management is defined by the near-universal, frequently refractory epilepsy that constitutes the dominant clinical risk across the lifespan — alongside intensive nutritional management, developmental therapy coordination, and cardiac surveillance — where the seizure severity, the clustering tendency, and the status epilepticus risk in this population make epilepsy monitoring platform availability and seizure tracking alert system reliability not merely clinical priorities but potential life-safety determinants.
Seizure tracking alert systems require heartbeat monitoring for life-safety protection. WHS individuals with nocturnal seizure clusters, convulsive seizure types, and status epilepticus history are at elevated risk for SUDEP (sudden unexpected death in epilepsy) and for status epilepticus-related hypoxic injury during unmoniored sleep — where seizure tracking alert systems using wearable seizure detectors, bed-based motion monitors, or video-based detection provide the earliest warning of nocturnal seizure events that allows caregivers to intervene, administer rescue medication, and call emergency services before a prolonged convulsive event produces hypoxic injury. Heartbeat monitoring at sub-minute intervals detects platform outages before they create unmonitored overnight exposure windows. Monitor seizure tracking alert systems at 30-second heartbeat intervals, 24/7.
Epilepsy monitoring platforms manage the dominant morbidity driver. The high medical refractoriness of WHS epilepsy — requiring sequential trials of anti-epileptic drugs including valproic acid, lamotrigine, levetiracetam, clobazam, clonazepam, rufinamide, and ketogenic diet, often with partial response and ongoing seizure breakthrough — means that epilepsy monitoring platforms tracking seizure diary records, EEG findings, anti-epileptic drug serum level records, dose adjustment records, adverse effect monitoring records, and status epilepticus emergency protocol documentation require consistent availability to support the anti-epileptic drug management decisions whose quality determines the seizure burden that shapes every aspect of the WHS individual's developmental trajectory, safety profile, and quality of life. Monitor epilepsy monitoring platforms at 1-minute intervals during clinical hours.
WHS patient registry platforms anchor evidence-based epilepsy management decisions. The WHS patient registry — collecting seizure type profiles, anti-epileptic drug treatment sequence and outcome records, ketogenic diet outcome records, and seizure-free period data from across the WHS population — provides clinicians with the population-level anti-epileptic drug efficacy and tolerability data that guides treatment sequencing decisions that cannot be informed by clinical trial data in a population too small and phenotypically variable for conventional randomized controlled trials. Registry platform failures during protocol queries or outcome submissions lose the evidence base for treatment sequencing decisions whose quality directly affects seizure burden outcomes. Monitor WHS registry platforms at 1-minute intervals during business hours.
Feeding and nutritional management platforms protect against malnutrition in a growth-restricted population. WHS individuals with growth retardation, hypotonia-related feeding difficulties, oropharyngeal dysphagia, and gastrostomy tube feeding dependence are at ongoing risk for nutritional inadequacy, micronutrient deficiency, and growth faltering whose early detection requires continuous nutritional monitoring platform availability — where feeding management platforms tracking tube feeding formula prescriptions, enteral nutrition volume and caloric intake records, weight and height velocity measurements, and dietitian consultation records require availability at every clinical contact where nutritional adequacy is assessed and feeding plan modifications are made. Monitor nutritional management platforms at 1-minute intervals during clinical hours.
Developmental therapy scheduling platforms determine the intensity of the therapeutic programs that drive developmental progress. WHS individuals with severe to profound intellectual disability, hypotonia, motor delay, communication limitation, and seizure burden require intensive physical therapy, occupational therapy, speech-language pathology, vision therapy, and behavioral support whose scheduling continuity — governed by developmental therapy scheduling platforms managing appointment calendars, therapist-patient assignments, therapy goal documentation, and surveillance interval compliance — determines whether the therapeutic intensity specified by the individual's developmental plan is actually delivered at the planned frequency. Monitor developmental therapy scheduling platforms during business hours.
What to Monitor on a Wolf-Hirschhorn Syndrome Tech Platform
WHS Patient Registry System
Monitor patient enrollment and demographic records, 4p16.3 deletion size characterization records (deletion breakpoints, size in Megabases, gene content), parental karyotype records identifying balanced translocations or inversions, genotype-phenotype correlation metadata, seizure type and onset age records, anti-epileptic drug treatment sequence and outcome records, ketogenic diet candidacy and outcome records, growth trajectory records, cardiac defect profiles, and natural history outcome records at 1-minute intervals during business hours. Alert immediately — WHS registry platform failures during a neurologist's protocol query for the anti-epileptic drug sequence used by other WHS programs for individuals with atonic and myoclonic seizure types who have failed valproic acid and lamotrigine delay the evidence-based anti-epileptic drug selection decision for the patient currently presenting with continued breakthrough seizures after a two-drug failure.
Epilepsy Monitoring Platform
Monitor seizure diary records documenting seizure type, frequency, duration, clustering patterns, and precipitant identification; EEG records including interictal epileptiform discharge pattern, ictal EEG correlates, and EEG response to anti-epileptic drug changes; anti-epileptic drug prescription and dose adjustment records; anti-epileptic drug serum trough level records and pharmacokinetic calculations; adverse effect monitoring records for hepatotoxicity, thrombocytopenia, and behavioral effects; ketogenic diet protocol records and ketone monitoring records; status epilepticus emergency protocol records including rescue benzodiazepine prescription and dose, emergency medical services contact information, and hospital treatment protocol documentation; status epilepticus hospitalization records; and epilepsy clinic multidisciplinary meeting records at 1-minute intervals during clinical hours. Alert immediately — epilepsy monitoring platform failures during an anti-epileptic drug adjustment appointment for a WHS child with myoclonic and atonic seizures who is being cross-titrated from valproic acid to rufinamide after breakthrough seizures on maximal tolerated valproic acid dose lose the seizure diary records and serum level documentation that the neurologist needs to determine the cross-titration schedule that minimizes breakthrough seizure exposure during the medication transition period.
Seizure Tracking Alert System (Heartbeat Monitoring)
Monitor wearable seizure detector connectivity and alert transmission records, bed-based motion detector and accelerometer connectivity records, video monitoring system connectivity and recording continuity records, caregiver alert notification delivery records, emergency response protocol activation records, nocturnal monitoring session start and end records, device battery and sensor status records, and seizure detection sensitivity and specificity calibration records at 30-second heartbeat intervals, 24/7. Alert immediately — seizure tracking alert system failures create unmonitored windows for WHS individuals with nocturnal convulsive seizure history whose overnight safety depends on the alert system detecting the motor signature of a tonic-clonic seizure and triggering a caregiver response within a timeframe that allows rescue benzodiazepine administration and, when necessary, emergency medical services activation before prolonged convulsive seizure duration produces hypoxic injury.
Feeding and Nutritional Management Platform
Monitor nasogastric tube feeding prescription and volume records, gastrostomy tube feeding formula prescription and caloric density records, enteral nutrition delivery system records, weight and length measurement records with growth velocity calculations, body mass index and nutritional status assessment records, micronutrient level monitoring records (including zinc, selenium, and fat-soluble vitamins in patients on enteral nutrition), feeding therapy assessment and oral feeding readiness records, modified barium swallow study and videofluoroscopic swallow study records, gastrostomy tube insertion operative records and post-placement care documentation, dietitian consultation records, and gastroenterology follow-up records during business and clinical hours. Alert immediately — nutritional management platform failures during a gastroenterology visit for a WHS toddler with a gastrostomy tube whose weight velocity has plateaued lose the nutritional intake records and weight velocity calculations that the dietitian and gastroenterologist need to determine whether the caloric density of the enteral formula should be increased or whether a malabsorptive process contributing to growth faltering should be investigated.
Developmental Therapy Scheduling Platform
Monitor physical therapy appointment scheduling records with session frequency compliance tracking, occupational therapy scheduling records for fine motor, sensory processing, and adaptive skills sessions, speech-language pathology scheduling records for communication and feeding therapy sessions, vision therapy appointment scheduling records, behavioral support scheduling records, early intervention IFSP service delivery scheduling records, school-based therapy scheduling records coordinated with IEP service hours, and therapy outcome record linkage records during business hours. Alert immediately — developmental therapy scheduling platform failures during the appointment booking cycle for a WHS infant's weekly physical therapy sessions — where the hypotonia, motor delay, and seizure burden that compound this infant's developmental trajectory make consistent physical therapy session delivery a critical component of the developmental intervention plan — create session gaps whose accumulation over the scheduling system downtime period represents lost developmental intervention opportunity in a developmental window where intervention intensity directly affects motor skill acquisition trajectories.
Cardiology and Congenital Heart Defect Surveillance
Monitor echocardiography records for ventricular and atrial septal defects, patent ductus arteriosus, and complex conotruncal anomaly hemodynamics; cardiac surgical operative records; post-repair surveillance echocardiography; and arrhythmia monitoring records at 1-minute intervals during clinical hours. Alert immediately — cardiology platform failures during echocardiography review for a WHS infant with a ventricular septal defect and recurrent respiratory infections lose the hemodynamic data that determines whether the pulmonary blood flow burden from the left-to-right shunt is contributing to the respiratory morbidity and whether surgical closure should be expedited.
Authentication and Patient Identity
Monitor authentication at 1-minute intervals, 24/7. WHS programs coordinate across genetics, neurology (epilepsy), nutrition and feeding, cardiology, developmental pediatrics, physical therapy, occupational therapy, speech-language pathology, behavioral support, and seizure monitoring — authentication failures simultaneously block every member of the multidisciplinary team managing a patient whose seizure burden, nutritional fragility, and profound intellectual disability make care coordination disruption a compounded safety and developmental risk.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, WHS registry interfaces, epilepsy monitoring platforms, seizure tracking alert systems, nutritional management platforms, developmental therapy scheduling systems, and cardiology platforms. Certificate errors disrupt the epilepsy monitoring, seizure alert, nutritional management, and developmental therapy workflows that define WHS care.
HIPAA and Genetic Privacy Considerations
Wolf-Hirschhorn Syndrome technology platforms handle sensitive PHI including 4p16.3 deletion records with direct parental karyotyping and prenatal recurrence risk implications, seizure frequency and severity records whose documentation affects guardianship and supervised care decisions, anti-epileptic drug serum level records, status epilepticus hospitalization records, intellectual disability severity assessments with educational and guardianship consequences, gastrostomy tube records documenting enteral nutrition dependence, and cardiac surgical records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing seizure tracking alert system records — where these records document the real-time safety monitoring that protects WHS individuals from undetected nocturnal convulsive seizures and status epilepticus, and where the failure of these records to correctly reflect the system's operational status creates a patient safety exposure whose potential consequence includes convulsive seizure-related mortality or hypoxic injury — privacy and availability standards must reflect HIPAA Security Rule compliance and the patient safety priority of 24/7 seizure alert system operational integrity. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for WHS programs managing genetic, epilepsy, nutritional, developmental, cardiovascular, and seizure monitoring PHI.
Alerting Strategy for Wolf-Hirschhorn Syndrome Tech Platforms
Immediate 24/7 heartbeat alerting for seizure tracking systems: Seizure tracking alert platforms monitored at 30-second heartbeat intervals, 24 hours a day, 7 days a week. System failures during overnight monitoring create patient safety exposure whose potential consequences include SUDEP and hypoxic injury from undetected nocturnal status epilepticus.
Immediate alerting during epilepsy clinical sessions: Epilepsy monitoring platforms during anti-epileptic drug adjustment, EEG review, and status epilepticus protocol consultation where documentation loss affects treatment sequencing and emergency management decisions.
Immediate alerting during nutritional management sessions: Feeding and nutritional management platforms during dietitian consultations, gastrostomy care visits, and nutritional adequacy assessments where growth faltering documentation determines formula escalation decisions.
Immediate alerting during registry queries: WHS patient registry during neurologist protocol queries where population-level anti-epileptic drug outcome data drives treatment sequencing decisions.
Immediate alerting for developmental therapy scheduling: Scheduling platforms during booking windows to prevent session gaps in the intensive therapy programs that drive developmental progress in the available neuroplasticity window.
Sustained-failure alert (10–15 minutes): Multi-specialty care coordination, orthopedics, and audiology platforms during business hours.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms WHS platform availability from the geographies where specialized chromosomal microdeletion epilepsy programs, pediatric neurology and epilepsy monitoring centers, seizure alert technology programs, and rare disease developmental pediatrics practices serve this population — important for a condition where the epilepsy severity, the seizure monitoring technology dependence, and the nutritional complexity concentrate comprehensive care in programs with specific expertise in medically refractory pediatric epilepsy and chromosomal deletion disorders.
Status Page for Wolf-Hirschhorn Syndrome Care Team Communication
A real-time status page gives pediatric neurologists managing anti-epileptic drug adjustments, dietitians monitoring enteral nutrition adequacy, seizure monitoring technologists tracking alert system connectivity, developmental therapy coordinators scheduling intensive therapy programs, cardiologists monitoring congenital heart defect surveillance, and geneticists reporting 4p16.3 deletion records immediate platform visibility without requiring inbound IT support contact. During a seizure tracking alert system outage in the early morning hours when a WHS child's wearable seizure detector loses connectivity, a status page enables the family to immediately confirm that the outage is system-wide and activate the caregiver manual monitoring protocol while waiting for platform restoration — preventing the scenario where the family believes the system is working while in fact the child is unmonitored.
Include the status page URL in seizure tracking system family emergency protocols, epilepsy clinical session downtime procedures, nutritional management backup protocols, developmental therapy scheduling contingency workflows, and WHS registry downtime notification plans.
Vigilmon Setup for Wolf-Hirschhorn Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Seizure tracking alert system (heartbeat) | 30 sec | PagerDuty (24/7, immediate) | | WHS patient registry system | 1 min | Slack + PagerDuty (business hours) | | Epilepsy monitoring platform | 1 min | Slack + PagerDuty (clinical hours) | | Feeding and nutritional management platform | 1 min | Slack + PagerDuty (clinical hours) | | Developmental therapy scheduling platform | 1 min | Slack + PagerDuty (business hours) | | Cardiology and congenital heart defect surveillance | 1 min | Slack + PagerDuty (clinical hours) | | Genetic counseling and 4p16.3 deletion records | 1 min | Slack + PagerDuty (business hours) | | Orthopedics and scoliosis surveillance | 2 min | Slack (business hours) | | Audiology and hearing management | 2 min | Slack (business hours) | | Patient and family emergency communication portal | 1 min | Slack + PagerDuty (24/7) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure seizure tracking alert systems at 30-second heartbeat intervals with immediate 24/7 PagerDuty alerting
- Add WHS patient registry systems with immediate business-hours alerting
- Configure epilepsy monitoring platforms with immediate clinical-hours alerting
- Add feeding and nutritional management platforms with immediate clinical-hours alerting
- Configure developmental therapy scheduling platforms with immediate business-hours alerting
- Add cardiology and congenital heart defect surveillance with immediate clinical-hours alerting
- Configure genetic counseling and 4p16.3 deletion record systems with immediate business-hours alerting
- Enable SSL certificate monitoring across all seizure tracking, epilepsy monitoring, nutritional management, therapy scheduling, cardiology, and registry domains
- Add the status page URL to seizure tracking family emergency protocols, epilepsy clinical session downtime procedures, and nutritional management backup protocols
Conclusion
Wolf-Hirschhorn Syndrome technology platforms are embedded in clinical decisions where seizure tracking alert system availability at 3:47 AM for a WHS six-year-old with a history of nocturnal tonic-clonic seizure clusters and two prior status epilepticus events who sleeps with a wearable seizure detector that is configured to alert the parents through the monitoring platform when accelerometer data matches the convulsive motor signature that the system was calibrated to detect for this child's specific seizure pattern — where the parents sleeping in the adjacent room with their phones configured to receive the alert depend on the platform processing the continuous accelerometer stream from the wearable device, matching the incoming data against the detection algorithm calibrated specifically for the cluster frequency and convulsive motor amplitude of this child's seizure type, transmitting the alert to the monitoring platform, and delivering the push notification to the parents' phones within a latency that allows them to reach this child within sixty seconds of seizure onset and administer the intranasal midazolam that the neurology team has prescribed as rescue medication — cannot fail at 3:47 AM when the platform downtime that produces a five-minute unmonitored window for a child whose previous status epilepticus lasted forty minutes and produced a three-day PICU admission represents not a service degradation but a patient safety event whose occurrence probability is not zero on any given night and whose consequence when it occurs is measured in minutes of convulsive seizure duration that the rescue medication could have terminated; where epilepsy monitoring platform availability during an anti-epileptic drug cross-titration appointment for a WHS child with atonic and myoclonic seizures who has failed valproic acid, lamotrigine, and levetiracetam sequentially and is now being cross-titrated to rufinamide — where the neurologist accessing the seizure diary records from the past three months to document the seizure type distribution and breakthrough frequency on the current regimen, the serum valproic acid trough level records to determine the safe rate of valproic acid withdrawal during the cross-titration, and the adverse effect monitoring records to identify whether the tremor and cognitive slowing that emerged during the valproic acid dose escalation phase have resolved sufficiently to proceed with taper — must access the complete epilepsy monitoring record to make the cross-titration schedule decisions whose correctness prevents the breakthrough seizure exposure during medication transition that the carefully staged withdrawal-and-introduction protocol is designed to minimize in a patient whose refractory epilepsy makes each new treatment attempt the product of the failed treatments that preceded it; where WHS patient registry platform availability during a neurologist's query for the seizure-free rate and adverse effect profile reported for rufinamide in WHS patients with atonic and myoclonic seizure types who failed the same three-drug sequence — where the neurologist using registry outcome data to determine whether the evidence base from other WHS programs supports rufinamide as the appropriate fourth-line agent or whether fenfluramine, a ketogenic diet, or a different agent has shown superior efficacy in the comparable population whose seizure profile, gene deletion size, and prior drug history most closely matches the patient currently in the clinic — determines whether the anti-epileptic drug selection decision is grounded in the WHS-specific evidence base or extrapolated from non-WHS refractory epilepsy populations whose treatment response may not reflect the 4p16.3 deletion mechanism; and where feeding and nutritional management platform availability during a gastroenterology review appointment for a WHS toddler whose weight has fallen from the 5th to below the 3rd percentile over the past four months despite the gastrostomy tube enteral nutrition protocol that was established at eighteen months — where the dietitian accessing the formula prescription records to confirm the current caloric density, the volume delivery records to determine whether the prescribed volume is actually being delivered consistently, the weight velocity calculation records to quantify the rate of growth faltering, and the micronutrient monitoring records to identify whether the growth faltering is accompanied by a micronutrient deficiency that would indicate malabsorption rather than simple caloric inadequacy must access the complete nutritional management record to determine whether the growth faltering should be addressed by caloric density increase, volume increase, formula change, or malabsorption workup — determines whether the growth intervention is targeted at the correct nutritional mechanism or applies caloric escalation to a malabsorptive process that caloric escalation alone will not address: a seizure tracking alert system failing at 3:47 AM when a child with nocturnal convulsive seizure history sleeps unmonitored in the adjacent room, an epilepsy monitoring platform unavailable when anti-epileptic drug cross-titration schedule decisions depend on seizure frequency, serum level, and adverse effect records, a WHS registry inaccessible when treatment sequencing depends on population-level anti-epileptic drug efficacy data, a nutritional management platform down when the growth faltering mechanism determines the appropriate formula intervention — these are not IT incidents. They are disruptions in the management of a chromosomal microdeletion syndrome where the near-universal refractory epilepsy, the nocturnal seizure monitoring technology dependence, the nutritional fragility, and the profound intellectual disability of affected individuals make every platform availability failure a compounded safety, clinical, and developmental risk across the overlapping domains whose intersection defines the care complexity of Wolf-Hirschhorn Syndrome.
Uptime monitoring gives Wolf-Hirschhorn Syndrome tech teams the detection capability to identify failures within seconds, trigger immediate care continuity procedures, and demonstrate to genetics programs, neurology and epilepsy monitoring services, seizure alert technology teams, nutritional management programs, developmental therapy practices, cardiology clinics, and compliance auditors that platform operational reliability matches the chromosomal microdeletion, epileptic, nutritional, developmental, and cardiovascular complexity of modern Wolf-Hirschhorn Syndrome care.
Start monitoring your Wolf-Hirschhorn Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #WolfHirschhornSyndrome #4p16deletion #chromosomalMicrodeletion #epilepsy #refractorySeizures #seizureAlert #SUDEP #statusEpilepticus #enteralNutrition #gastrostomy #intellectualDisability #patientRegistry #rareDisease #HIPAA #healthtech #digitalhealth #uptime #sre